JPH0520415B2 - - Google Patents

Info

Publication number: JPH0520415B2
Authority: JP; Japan
Prior art keywords: cells; cell; cytotoxic; graft; host
Prior art date: 1983-06-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP58103570A

Other languages

English (en)

Japanese (ja)

Other versions

JPS59231020A (ja

Inventor

Fuaburishiusu Hansuuake

Ururitsuhi Ketsutogen Etsukaato

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SHANKUSUBIRU CORP NV

Original Assignee

SHANKUSUBIRU CORP NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-06-11

Filing date

1983-06-11

Publication date

1993-03-19

1983-06-11 Application filed by SHANKUSUBIRU CORP NV filed Critical SHANKUSUBIRU CORP NV

1983-06-11 Priority to JP58103570A priority Critical patent/JPS59231020A/ja

1984-12-25 Publication of JPS59231020A publication Critical patent/JPS59231020A/ja

1993-03-19 Publication of JPH0520415B2 publication Critical patent/JPH0520415B2/ja

Status Granted legal-status Critical Current

Links

210000004027 cell Anatomy 0.000 claims description 33
210000001744 T-lymphocyte Anatomy 0.000 claims description 19
230000015572 biosynthetic process Effects 0.000 claims description 6
210000000056 organ Anatomy 0.000 claims description 5
206010052779 Transplant rejections Diseases 0.000 claims description 4
230000001404 mediated effect Effects 0.000 claims description 4
230000035755 proliferation Effects 0.000 claims description 4
239000003125 aqueous solvent Substances 0.000 claims description 2
239000003791 organic solvent mixture Substances 0.000 claims description 2
239000000203 mixture Substances 0.000 claims 1
150000002270 gangliosides Chemical class 0.000 description 15
108010002350 Interleukin-2 Proteins 0.000 description 14
102000000588 Interleukin-2 Human genes 0.000 description 14
239000012636 effector Substances 0.000 description 13
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 12
210000002540 macrophage Anatomy 0.000 description 9
239000002981 blocking agent Substances 0.000 description 8
238000000034 method Methods 0.000 description 7
239000001963 growth medium Substances 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
231100000433 cytotoxic Toxicity 0.000 description 5
230000001472 cytotoxic effect Effects 0.000 description 5
210000001185 bone marrow Anatomy 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
VELGMVLNORPMAO-JTFNWEOFSA-N n-[(e)-1-[(3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxym Chemical compound O[C@@H]1[C@@H](O)C(OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 VELGMVLNORPMAO-JTFNWEOFSA-N 0.000 description 4
102000000589 Interleukin-1 Human genes 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000011651 chromium Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003018 immunosuppressive agent Substances 0.000 description 3
229940124589 immunosuppressive drug Drugs 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000000822 natural killer cell Anatomy 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000009466 transformation Effects 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
108010073633 blastogenic factor Proteins 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229910052804 chromium Inorganic materials 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
210000004153 islets of langerhan Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
238000011282 treatment Methods 0.000 description 2
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
206010067268 Post procedural infection Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
-1 antibodies Proteins 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000001642 comitogenic effect Effects 0.000 description 1
150000001887 cortisones Chemical class 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
229940054244 gangliosides and ganglioside derivative Drugs 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
150000002339 glycosphingolipids Chemical class 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000002523 lectin Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000000693 micelle Substances 0.000 description 1
230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
241000894007 species Species 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

JP58103570A 1983-06-11 1983-06-11 製薬学的組成物 Granted JPS59231020A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP58103570A JPS59231020A (ja)	1983-06-11	1983-06-11	製薬学的組成物

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP58103570A JPS59231020A (ja)	1983-06-11	1983-06-11	製薬学的組成物

Publications (2)

Publication Number	Publication Date
JPS59231020A JPS59231020A (ja)	1984-12-25
JPH0520415B2 true JPH0520415B2 (fr)	1993-03-19

Family

ID=14357454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP58103570A Granted JPS59231020A (ja)	1983-06-11	1983-06-11	製薬学的組成物

Country Status (1)

Country	Link
JP (1)	JPS59231020A (fr)

1983
- 1983-06-11 JP JP58103570A patent/JPS59231020A/ja active Granted

Also Published As

Publication number	Publication date
JPS59231020A (ja)	1984-12-25

Publication	Publication Date	Title
US5028594A (en)	1991-07-02	Use of photodynamic compositions for cytotoxic effects
Weringer et al.	1985	Immune attack on pancreatic islet transplants in the spontaneously diabetic BioBreeding/Worcester (BB/W) rat is not MHC restricted.
Bekesi et al.	1976	Treatment of spontaneous leukemia in AKR mice with chemotherapy, immunotherapy, or interferon
US6013641A (en)	2000-01-11	Use of hyaluronic acid as an immunosuppressant
Bradley et al.	1986	Desferrioxamine treatment prevents chronic islet allograft damage
US5681556A (en)	1997-10-28	Method and compositions for suppressing allograft rejection in mammals
US4388309A (en)	1983-06-14	Process for suppressing graft rejection in organ transplantation
US5504092A (en)	1996-04-02	Use of Linomide to increase hemopoietic cell precursors
JPS63183528A (ja)	1988-07-28	悪性腫瘍治療剤
GB2106935A (en)	1983-04-20	Cancer cell-combatting lymphocytes process, for the production thereof, and anticancer agents containing said lymphocytes
JPH0520415B2 (fr)	1993-03-19
EP0126817B1 (fr)	1989-04-19	Suppression du rejet de greffe dans la transplantation d'organe
EP0426924A1 (fr)	1991-05-15	Production de compositions avec la propriété de transporter des métaux pour faciliter la greffe de moelle osseuse histo-incompatible et pour contrôler les réactions immunes dans l'hôte
WO1992003049A1 (fr)	1992-03-05	Procedes et compositions de traitement de maladies induites par les lymphocytes t
Chester et al.	1977	Further development of a successful protocol of graft versus leukemia without fatal graft-versus-host disease in AKR mice
US4772469A (en)	1988-09-20	Production of lymphoid tissue effector cells reactive against cancer cells by means of MER, and use thereof in cancer therapy
EP0522001B1 (fr)	1996-06-26	Utilisation de soutien de linomide (r)
JPH06135836A (ja)	1994-05-17	コントラサプレッサー細胞の誘導剤
FI77157B (fi)	1988-10-31	Foerfarande foer framstaellning av glykobunden antigen och foerfarande foer framstaellning av foer kancerceller toxiska lymfocyter, som aer specifika mot denna antigen.
CA2216599A1 (fr)	1996-10-10	Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et composition les contenant
JP2837856B2 (ja)	1998-12-16	リンフォカイン活性化キラー細胞及びその製造法
JPH04503365A (ja)	1992-06-18	固体臓器移植における移植組織拒絶反応を防止する方法
BOWERS et al.	0	15th International Leucocyte Culture Conference December 5-10, 1982. Asilomar
Marrow	1958	Effects of Donor and Host Lymphoid and Myeloid Tissue Injections in Le-thally X-irradiated Mice Treated with Rat Bone Marrow 1, 2, 3
Hutchinson	1984	Cyclosporin A. A powerful immunosuppressant in the rat